Table 2 Clinical variables and PBSC... | American Society of Hematology

Table 2

Clinical variables and PBSC graft cell subset doses tested in univariate analysis

Variables*	Cumulative incidence of grade II-IV aGVHD, % (95% CI)	P
TBI		.26
TBI/Cy (n = 39)	51 (34-66)
Non-TBI (n = 18)	39 (16-61)
Recipient age		.91
< 47.2 y	46 (27-63)
≥ 47.2 y	48 (29-65)
Donor age		.85
< 47.5 y	46 (27-64)
≥ 47.5 y	48 (29-65)
Sex mismatch		.46
Yes (n = 19)	50 (33-65)
No (n = 38)	42 (20-63)
Disease risk†		.74
Standard (n = 16)	44 (19-66)
High (n = 41)	49 (36-63)
Conditioning		.53
Myeloablative (n = 41)	44 (19-67)
RIC (n = 16)	49 (33-63)
Diagnosis		.038
CML (n = 18)	61 (34-80)
Other (n = 39)	41 (25-56)
CD34⁺ cells		.52
< 5.66 × 10⁶ cells/kg of body weight	54 (33-70)
≥ 5.66 × 10⁶ cells/kg of body weight	41 (23-59)
NK cells		.28
< 11.7 × 10⁶ cells/kg of body weight	39 (21-57)
≥ 11.7 × 10⁶ cells/kg of body weight	55 (35-71)
B cells		.12
< 33.5 × 10⁶ cells/kg of body weight	57 (36-73)
≥ 33.5 × 10⁶ cells/kg of body weight	38 (20-55)
T cells		.24
< 154 × 10⁶ cells/kg of body weight	54 (32-70)
≥ 154 × 10⁶ cells/kg of body weight	41 (23-58)
CD4⁺ T cells		.71
< 91.2 × 10⁶ cells/kg of body weight	46 (27-64)
≥ 91.2 × 10⁶ cells/kg of body weight	48 (29-65)
CD8⁺ T cells		.09
< 40.3 × 10⁶ cells/kg of body weight	57 (36-73)
≥ 40.3 × 10⁶ cells/kg of body weight	38 (20-55)
Tregs		.6
< 4.9 × 10⁶ cells/kg of body weight	50 (30-67)
≥ 4.9 × 10⁶ cells/kg of body weight	45 (26-61)
CD3⁺CD161⁺ cells		.62
< 7.07 × 10⁶ cells/kg of body weight	46 (27-64)
≥ 7.07 × 10⁶ cells/kg of body weight	48 (28-65)
iNKT cells		.014
< 0.057 × 10⁶ cells/kg of body weight	64 (43-79)
≥ 0.057 × 10⁶ cells/kg of body weight	31 (15-48)
CD4⁺ iNKT cells		.002
< 0.026 × 10⁶ cells/kg of body weight	68 (46-82)
≥ 0.026 × 10⁶ cells/kg of body weight	26 (13-45)
CD4⁻ iNKT cells		.0008
< 0.031 × 10⁶ cells/kg of body weight	71 (50-85)
≥ 0.031 × 10⁶ cells/kg of body weight	24 (10-41)

Variables*	Cumulative incidence of grade II-IV aGVHD, % (95% CI)	P
TBI		.26
TBI/Cy (n = 39)	51 (34-66)
Non-TBI (n = 18)	39 (16-61)
Recipient age		.91
< 47.2 y	46 (27-63)
≥ 47.2 y	48 (29-65)
Donor age		.85
< 47.5 y	46 (27-64)
≥ 47.5 y	48 (29-65)
Sex mismatch		.46
Yes (n = 19)	50 (33-65)
No (n = 38)	42 (20-63)
Disease risk†		.74
Standard (n = 16)	44 (19-66)
High (n = 41)	49 (36-63)
Conditioning		.53
Myeloablative (n = 41)	44 (19-67)
RIC (n = 16)	49 (33-63)
Diagnosis		.038
CML (n = 18)	61 (34-80)
Other (n = 39)	41 (25-56)
CD34⁺ cells		.52
< 5.66 × 10⁶ cells/kg of body weight	54 (33-70)
≥ 5.66 × 10⁶ cells/kg of body weight	41 (23-59)
NK cells		.28
< 11.7 × 10⁶ cells/kg of body weight	39 (21-57)
≥ 11.7 × 10⁶ cells/kg of body weight	55 (35-71)
B cells		.12
< 33.5 × 10⁶ cells/kg of body weight	57 (36-73)
≥ 33.5 × 10⁶ cells/kg of body weight	38 (20-55)
T cells		.24
< 154 × 10⁶ cells/kg of body weight	54 (32-70)
≥ 154 × 10⁶ cells/kg of body weight	41 (23-58)
CD4⁺ T cells		.71
< 91.2 × 10⁶ cells/kg of body weight	46 (27-64)
≥ 91.2 × 10⁶ cells/kg of body weight	48 (29-65)
CD8⁺ T cells		.09
< 40.3 × 10⁶ cells/kg of body weight	57 (36-73)
≥ 40.3 × 10⁶ cells/kg of body weight	38 (20-55)
Tregs		.6
< 4.9 × 10⁶ cells/kg of body weight	50 (30-67)
≥ 4.9 × 10⁶ cells/kg of body weight	45 (26-61)
CD3⁺CD161⁺ cells		.62
< 7.07 × 10⁶ cells/kg of body weight	46 (27-64)
≥ 7.07 × 10⁶ cells/kg of body weight	48 (28-65)
iNKT cells		.014
< 0.057 × 10⁶ cells/kg of body weight	64 (43-79)
≥ 0.057 × 10⁶ cells/kg of body weight	31 (15-48)
CD4⁺ iNKT cells		.002
< 0.026 × 10⁶ cells/kg of body weight	68 (46-82)
≥ 0.026 × 10⁶ cells/kg of body weight	26 (13-45)
CD4⁻ iNKT cells		.0008
< 0.031 × 10⁶ cells/kg of body weight	71 (50-85)
≥ 0.031 × 10⁶ cells/kg of body weight	24 (10-41)

TBI indicates total body irradiation; Cyclo, cyclophosphamide; and RIC, reduced intensity conditioning.

Median values are shown.

†

Standard risk indicates CML chronic phase 1, acute myeloid leukemia/acute lymphoblastic leukemia standard risk in first complete remission; and high risk, all other.

View Large

This Feature Is Available To Subscribers Only